| 摘要 |
Disclosed is the use of deoxypeganine, as free base or as acid addition salt, for the manufacture of a medicament for the treatment of: chronic, cerebral or central nervous defunctionalization manifestations or chronic psychiatric symptoms which occur as sequelae caused by dependency on addictive substances or intoxicants, or as sequelae caused by occasional or chronic abuse of addictive substances or intoxicants, wherein said sequelae persist even after a withdrawal therapy has been successfully completed; or of chronic, cerebral or central nervous defunctionalization manifestations or chronic psychiatric symptoms which occur as sequelae caused by occasional or chronic abuse of medicines; or of cerebral, central nervous or chronic psychiatric symptoms, defunctionalization manifestations or diseases which occur as side effects of use of medicaments when these medicaments are used as intended; or of cerebral, central nervous or chronic psychiatric symptoms, defunctionalization manifestations or diseases which occur as a result of acute poisoning by psychotropic toxic substances; or of cerebral, central nervous or chronic psychiatric symptoms, defunctionalization manifestations or diseases which occur as a result of chronic exposure to psychotropically active toxic substances; or of cerebral, central nervous or chronic psychiatric symptoms, defunctionalization manifestations or diseases which occur as a result of chronic exposure to environment poisons; wherein said symptoms, defunctionalization manifestations or diseases are cognitive disturbances which occur in humans or other vertebrates.
|
